The following research supported by the Kaiser Permanente Institute for Health Policy was published in 2024:
- Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ. 2024;386:e079126.
- Rome BN, Kesselheim AS, Feldman WB. Medicare’s first round of drug-price negotiation – measuring success. New England Journal of Medicine 2024 Oct 16.
- Horrow C, Kesselheim AS. Regulating laboratory tests: what framework would best support safety and validity? Milbank Quarterly 2024 May 13.
- Bhargava R, Brown N, Kapczynski A, Kesselheim AS, Lim SY, Morten CJ. The constitutionality of Medicare drug-price negotiation under the takings clause. Journal of Law, Medicine and Ethics. Epub 2024 Mar 13.
- Kesselheim AS, Bhaskar A. Comments in Response to the NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-in Rights. February 6, 2024. Available on-line at https://www.regulations.gov/comment/NIST-2023-0008-0767
- Ge AY, Feldman WB, Kaiser MF, Rejeski K, Iacoboni G, Dickinson MJ, Kesselheim AS, Cliff ERS. Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia. 66th Annual American Society of Hematology Annual Meeting Abstract #3659. December 8, 2024.